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The Patentability of Antibodies for Use in Medications After Amgen v. Sanofi
By: Kaitlyn Taylor
Introduction
Taking medication is an important part of the daily routine of many individuals. For many, taking
various medications, either prescription or over the counter, can prove to have a plethora of benefits such
as fighting disease, managing chronic illness, and improving overall quality of life. Accordingly, a large
number of medications enter the market every year. In 2020, 53 drugs received approval from the U.S.
Food and Drug Administration (“FDA”),1 and as of October 2021, 37 medications received FDA
approval.2 The process for researching and developing medications for approval and entrance into the
market is incredibly long, arduous, and expensive.3 A critical step in this process is patenting the drug to
protect the manufacturer's invention.
There are many different patent types that allow pharmaceuticals to be patented; however, a
recent case has caused a shift in how one particular class of pharmaceuticals, proprotein convertase
subtilisin kexin type 9 (“PCSK9”) inhibitors, are patented.4 In February 2021, the U.S. Court of Appeals
for the Federal Circuit ruled on Amgen v. Sanofi, an important case that will drastically impact the
patentability of PCSK9 inhibitors.5 This case centered around patents for medications utilizing antibodies,
which are also known as immunoglobulins.6 The court invalidated two Amgen patents covering PCSK9
inhibitor monoclonal antibody drugs, used for lowering cholesterol.7 The antibodies utilized in Amgen’s
drug, Repatha (generically known as evolocumab), lowers low-density lipoprotein ("LDL") cholesterol.8

1

See Food & Drug Admin., Novel Drug Approvals for 2020 (Oct. 8, 2021), https://perma.cc/6WGX-8LN7 (last
visited Oct. 9, 2021).
2
See Food & Drug Admin., Novel Drug Approvals for 2021 (Oct. 8, 2021), https://perma.cc/7AEK-BRRT (last
visited Oct, 9, 2021).
3
Dani Kass, Pharma Giants Tee Up Biologics Innovation Fight At Fed. Circ. (Aug. 21, 2020)
https://perma.cc/2QNH-7J6D (last visited Oct. 15, 2021).
4
Amgen Inc. v. Sanofi, 987 F.3d 1080, 1082 (Fed. Cir. 2021).
5
Id. at 1083.
6
See NEIL A. CAMPBELL ET AL., CAMPBELL BIOLOGY 953 (Beth Wilbur et al. eds., 10th ed. 2014).
7
Jane Byrne, Amgen v. Sanofi ruling: It is time to kiss goodbye to broad, functional patent claims for antibodies,
BioPharma Rep. (Mar. 25, 2021), https://perma.cc/4WHH-ETCD (last visited Oct. 9, 2021).
8
Amgen, 987 F.3d at 1082.
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Repatha can lower LDL cholesterol by binding to the PCSK9 protein and blocking PCSK9 from binding
to LDL receptors.9
In ruling on this case, the court stated that the functional claims within the patents for these
antibodies were too broad.10 This ruling essentially eliminated the ability to define an antibody within the
patent application purely based on the antibody’s function.11 This is a shift in the precedent previously
governing the patentability of these monoclonal antibodies, which could impact and cause issues for
applications and patents that were drafted several years ago, as well as future patents.12 Therefore, due to
this shift in precedent, Amgen has and will continue to substantially impact the patentability of antibodies
for use in medications.
This article aims to discuss the impact that the Amgen decision has had, and will continue to have,
on the process and patentability of antibodies for use in medications. Additionally, this article aims to
discuss the impact that the Amgen decision could have on attempts to patent antibodies for use in new
medications moving forward. This article is organized into five subsequent sections, the first of which
will provide a brief overview of the United States patent system and background information regarding
antibodies. After this, this article will provide an overview of the patentability of antibodies and the patent
process regarding antibodies for use in medications prior to the Amgen decision. Then, this article will
discuss and provide an overview of the Amgen case itself. Next, this article will discuss Amgen’s impact
on the patentability of antibodies for use in medications and the patent process itself. Finally, this article
will conclude with a section detailing the impact that the Amgen decision could have on future attempts to
patent antibodies for use in new medications moving forward.
Background
A Brief History of Patents in the United States

9

Id.
Jane Byrne, Amgen v. Sanofi ruling: It is time to kiss goodbye to broad, functional patent claims for antibodies,
BioPharma Rep. (Mar. 25, 2021), https://perma.cc/4WHH-ETCD (last visited Oct. 9, 2021).
11
Id.
12
Id.
10
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To discuss the patentability of antibodies, one must understand the patent system and process
within the United States. The Constitution of the United States laid out the initial framework for the
governance of patents and patent law.13 “Congress shall have power . . . to promote the progress of
science and useful arts, by securing for limited times to authors and inventors the exclusive right to their
respective writings and discoveries.” (the “Intellectual Property Clause”).14 England’s approach in the
Statute of Monopolies was the initial basis for this concept, which granted limited monopolies for
inventions.15
Although the Intellectual Property Clause initially set forth a basis for patent law, the first patent
laws in the United States were not passed until the Patent Act of 1790 (“the 1790 Act”).16 The 1790 Act
intended to promote the progress of the useful arts and grant a term of up to fourteen years of protection
for inventions that could be deemed adequately important and useful.17 However, several years later, the
1790 Act was repealed and replaced with the Patent Act of 1793, which contains the definition for what
constitutes subject matter that is patentable, and this definition has predominantly remained unchanged.18
There are four primary categories that define patentable subject matter: processes, machines,
manufactures, and compositions of matter.19 Anything for which one is seeking patent protection must fall
into at least one of these four categories.20 Additionally, patentable subject matter does not include
abstract ideas, laws of nature, and natural phenomena.21 Therefore, anything that can be defined as one of

13

A Brief History of Patent Law in the United States (May 7, 2014), https://perma.cc/C75E-Q466 (last visited Oct.
9, 2021).
14
U.S. CONST. art. I, § 8.
15
A Brief History of Patent Law in the United States (May 7, 2014), https://perma.cc/C75E-Q466 last visited Oct.
9, 2021).
16
Id.
17
Id.
18
Id.
19
2106 PATENT SUBJECT MATTER ELIGIBILITY [R-10.2019], https://perma.cc/BXT7-XTW2 (last visited Oct. 15,
2021).
20
Id.
21
Id.
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these exceptions is not patentable subject matter, even if it falls into one of the four previously mentioned
categories.22
The current patent system dictates that any individual who creates or discovers something that is
“new and useful” may obtain a patent for that new invention.23 However, for a patent to be granted, an
invention must satisfy three requirements.24 It must: (1) be novel, (2) have utility, and (3) be nonobvious.25 In a patent application, the claim defines the patentable subject matter for which one is seeking
protection.26 Claims function to describe and define precisely what would be protected if the patent
application were to be granted so that it is clear exactly what is and what is not protected in regards to the
patentable subject matter.27 Additionally, all patent applications must contain a written description
supporting the claim of the invention and the process in which it is made using specific, clear, and concise
terms, along with all of the other additional specifications as they are laid out in the written description
requirement.28 In Amgen, the written description portion of the patents was the primary area of dispute
and it is that portion where the court’s ruling had the greatest effect.29
Another important aspect of the current patent system is the enablement requirement, which
refers to a specific section of a patent application where one must describe how to make and use the
invention.30 For this requirement to be satisfied, one who is skilled in the art must be able to make and use
the invention that is defined within the claim in that patent application.31 Therefore, if a patent applicant
has sufficiently informed one who is skilled in that particular art how to make and use the invention
within the patent application, then the enablement requirement is satisfied.32

22

Id.
35 U.S.C.S. §§101-103 (2021).
24
Id.
25
Id.
26
1824 THE CLAIMS [R-07.2015], https://perma.cc/JS94-DQ3F (last visited Oct. 15, 2021).
27
Id.
28
35 U.S.C.S. § 112 (2021).
29
Amgen Inc. v. Sanofi, 987 F.3d 1080, 1084 (Fed. Cir. 2021).
30
2164 THE ENABLEMENT REQUIREMENT [R-11.2013], https://perma.cc/A6BH-XCN9 (last visited Oct. 15, 2021).
31
Id.
32
Id.
23

4
https://scholarship.law.uc.edu/ipclj/vol6/iss1/7

4

Taylor: The Patentability of Antibodies for Use in Medications After Amge

What is an Antibody?
To discuss the patentability of antibodies, one must understand antibodies themselves.
Essentially, an antibody is a protein component of the body’s immune system that circulates throughout
the bloodstream and works to recognize and neutralize a plethora of foreign substances (called antigens)
such as viruses and bacteria.33 Antibodies are proteins, and proteins are molecules that are made up of one
or more polypeptides (a large group of amino acids) that are then folded and coiled into a threedimensional structure.34 Antibodies are produced and secreted by B cells which function as a part of the
body’s adaptive immune system.35
Antibodies have a very distinct Y-shaped protein structure.36 This structure is made up of four
polypeptide chains grouped into two identical pairs, two heavy chains and two light chains.37 These
chains are linked together with disulfide bridges.38 Due to the Y-shaped structure of antibodies, the two
“hands” serve as antigen binding sites while the “tail” binds to various receptors on the surface of the
cell.39 The “tail” of an antibody cannot change, and thus is also known as its constant region; whereas, the
hands of an antibody can change through the process of binding to antigens, and thus, are known as the
variable region.40 Additionally, the “tail” of the antibody serves as the identifier to determine the
antibody’s class.41 There are five different classes of antibodies: IgG, IgA, IgD, IgE, and IgM.42 Each
antibody class serves a different purpose and has varying levels of frequency in the blood.43 However, the

33

Antibody, NATIONAL HUMAN GENOME RESEARCH INSTITUTE, https://perma.cc/47JH-CJQM (last visited Sept. 24,
2021).
34
See NEIL A. CAMPBELL ET AL., CAMPBELL BIOLOGY 953 (Beth Wilbur et al. eds., 10th ed. 2014).
35
Id. at 953.
36
Id.
37
Id.
38
Id.
39
LAUREN M. SOMPAYRAC, HOW THE IMMUNE SYSTEM WORKS 4 (4th ed. 2012)
40
Id.
41
Id.
42
Mark Chiu et al., Antibody Structure and Function: The Basis for Engineering Therapeutics, MDPI, Dec. 3, 2019,
at 1, 2.
43
Id.
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vast majority of antibodies in the blood are IgG antibodies.44 The antibodies utilized in the drug Repatha,
discussed in the Amgen case, are grouped in the IgG class of antibodies.45
In medications, antibodies serve a wide variety of purposes and functions, working to treat and
manage symptoms of many different illnesses and conditions.46 Because of their high specificity in
treating and managing illness, therapeutic antibodies used in medications have fewer adverse side effects
when compared to traditional therapeutics.47 Due to this, therapeutic antibodies have become the
predominant class of new drugs developed over the past several years, with many of the best-selling drugs
worldwide utilizing antibodies.48 There are several different antibody engineering technologies used to
develop these medications. However, the type of antibody in the medication at issue in Amgen, is a
monoclonal antibody (“mAbs”).49
Monoclonal antibodies are produced by B cells, and they work to specifically target antigens.50
When used in medication, mAbs should have several essential biophysical properties such as high
stability, high binding activity for antigens, and low immunogenicity.51 One example of a monoclonal
antibody is in the drug Humira (generically known as Adalimumab), which is in the IgG class of
antibodies and generates a significant immune response.52
The monoclonal antibody whose patent was at issue in Amgen binds to PCSK9, which inhibits
LDL cholesterol regulation.53 An elevated LDL cholesterol can cause heart disease.54 LDL receptors work
to remove the amount of LDL cholesterol from the bloodstream, which serves as a regulatory method for

44

LAUREN M. SOMPAYRAC, HOW THE IMMUNE SYSTEM WORKS 4 (4th ed. 2012).
REPATHA PRESCRIBER INFORMATION, https://perma.cc/63QC-5LZ2 (last visited Sept. 24, 2021).
46
MONOCLONAL ANTIBODY DRUGS FOR CANCER: HOW THEY WORK, https://perma.cc/8XGE-CGXB (last visited Oct.
15, 2021).
47
Ruei-Min Lu et al., Development of therapeutic antibodies for the treatment of diseases, J. Biomedical Sci., Jan.
2020 at 1, 1 https://perma.cc/4U5Q-DGNL.
48
Id.
49
Amgen, 987 F.3d at 1083.
50
Ruei-Min Lu et al., Development of therapeutic antibodies for the treatment of diseases, J. Biomedical Sci., Jan.
2020 at 1, 1 https://perma.cc/4U5Q-DGNL.
51
Id. at 12.
52
Id.
53
Amgen, at 1083.
54
Id. at 1082.
45
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LDL cholesterol.55 PCSK9 works to regulate the degradation of LDL receptors by binding to the LDL
receptors and mediating their degradation, which ultimately decreases the number of LDL receptors
present on the surface of the cell.56 Antibodies, such as those utilized in Amgen’s drug Repatha, bind to
PCSK9 and block it, allowing the LDL receptors to continue performing their regulatory function of LDL
cholesterol.57 In binding to PCSK9 and inhibiting the binding of PCSK9 to LDL, this antibody increases
the number of available LDL receptors, thereby lowering LDL cholesterol.58
The scientific definition, description, and understanding of antibodies are based primarily on the
antibody’s protein structure and primary function.59 However, the legal definition and understanding of
antibodies as it relates to patentability is slightly different.60 When it comes to the patentability of an
antibody, the legal system views that antibody merely as it is described and defined within the elements of
its claim.61 With Repatha, scientifically, the antibodies in this medication would be described based upon
their function, to bind to PCSK9 and thereby lower LDL cholesterol.62 However, legally, they would be
defined based upon how they are described in the written claims portion of the patent pertaining to this
drug: an isolated monoclonal antibody that when bound to PCSK9, binds to one of many residues.63 This
demonstrates a difference in the understanding, description, and definition of an antibody between the
scientific and legal perspectives. The scientific understanding is based on the antibody’s structure and
function whereas the legal understanding is based upon the claims in the antibody’s patent application.
These differences could lead to a misunderstanding regarding what is actually claimed and therefore
protected by a particular patent. This then leaves room for the United States Patent and Trademark Office,

55

Id.
Id. at 1083.
57
Id.
58
REPATHA PRESCRIBER INFORMATION, https://perma.cc/63QC-5LZ2 (last visited Sept. 24, 2021).
59
Antibody, NATIONAL HUMAN GENOME RESEARCH INSTITUTE, https://perma.cc/47JH-CJQM (last visited Sept. 24,
2021).
60
MONOCLONAL ANTIBODY PATENTS: EVOLVING LAW & STRATEGIES, (Oct. 1, 2012) https://perma.cc/BC96-CWY7
(Oct. 15, 2021).
61
Id.
62
REPATHA PRESCRIBER INFORMATION, https://perma.cc/63QC-5LZ2 (last visited Sept. 24, 2021).
63
Amgen, at 1083.
56
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as well as the court system, to deal with these discrepancies and disputes as they arise, clarifying for
scientists exactly what they have and have not claimed in regard to the antibodies they are attempting to
patent.
How were Antibodies Patented in the Past?
To discuss the changes to antibody patentability following the decision in Amgen, one must also
understand the process of patenting antibodies prior to this decision. As mentioned previously, all
inventions to be patented must meet three criteria: (1) novelty, (2) utility, and (3) nonobviousness, and
this includes antibodies for use in medications.64 Additionally, all inventions to be patented must adhere
to the written requirements and disclosures of 35 U.S.C.§ 112.65 However, satisfying this written
requirement is often the primary focus of litigation in patent suits where individuals claim infringement of
antibody patents as used in medication.66 In these suits, courts must determine what level of specificity
must be listed within the claim to adequately satisfy the written requirement laid out in 35 U.S.C. § 112.67
This discussion of the written requirement, specifically the enablement requirement, and whether or not
these requirements are satisfied, is the primary focus of the litigation in the Amgen case.68
Georges J. F Köhler and César Milstein were the first individuals who introduced a technique that
allowed for the creation of monoclonal antibodies in large amounts.69 However, the pair of scientists were
not able to obtain a patent for their techniques, given that their work had been featured in an article in
Nature, and British patent law prevents any work that has been previously disclosed in a medium such as
a publication from being included in an application for a patent.70 Additionally, they did not obtain a
patent in the United States, as they took no action to file for a patent.71 The first patents in the United

64

35 U.S.C.S. §§ 101-103 (2021).
35 U.S.C.S. § 112 (2021).
66
Laura Labeots, The Written Description Requirement, Healthcare Law Insights, Dec. 17, 2014,
https://perma.cc/M379-GUDF (last visited Oct. 15, 2021).
67
Id.
68
Amgen, 987 F.3d at 1083.
69
Ruei-Min Lu et al., Development of therapeutic antibodies for the treatment of diseases, J. Biomedical Sci., Jan.
2020 at 1, 1 https://perma.cc/4U5Q-DGNL.
70
A Missed Opportunity? The Patent Saga, WHAT IS BIO TECHNOLOGY (2017), https://perma.cc/SAC4-N2GT.
71
Id.
65
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States for monoclonal antibodies used in a clinical setting (to fight tumors and influenza virus antigens)
were awarded a few years later in late 1979 and early 1980 to Koprowski, Croce, and Gerhard.72 This was
controversial in Britain as well as the scientific community at large given that many individuals felt as
though they were merely copying Köhler and Milstein’s technique.73 After this patent was granted, claims
shifted from patenting the process of creating the antibody utilized in a particular medication, to claims
that were instead focused on patenting the antibody itself.
There is a substantial body of law that relates either to the patenting of antibodies or the written
requirement portion of the patent application process. Given that this body of law is so large, this article
will highlight only a few significant cases that provide important background and precedent on these
issues before the ruling in Amgen. The following four cases will provide insight and understanding into
the process of patenting antibodies as well as the court’s understanding and interpretation of the written
requirement portion of the patent application process.
This first case provides a general insight into the patenting of monoclonal antibodies. In a 2015
case before the U.S. District Court for the Eastern District of Virginia, the plaintiff, UCB, brought suit
against Yeda Research & Development Company, stating that UCB’s monoclonal antibody drug, Cimzia,
did not infringe on Yeda’s patent and that Yeda’s patent was invalid.74 The court held that in the written
description, using the term “monoclonal antibody” limited the term to an antibody that was generated in a
specific manner and not through other processes.75 The court further defined a monoclonal antibody as a
grouping of a single type of antibody that was generated in that specific manner.76 This case essentially
set up the court’s interpretation of a monoclonal antibody as it was defined through the written
requirement of a patent application.77 This interpretation by the court provided a standardized method of

72

Id.
Id.
74
UCB, Inc. v. Yeda Research & Dev. Co., 117 F. Supp. 3d 755, 759 (E.D. Va. 2015).
75
Id.
76
Id.
77
Id.
73
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determining exactly what a monoclonal antibody is so that it does not need to be continuously defined in
future applications.78
Regents of Univ. of Cal. v. Eli Lilly & Co., provides a baseline analysis and understanding
regarding the courts’ interpretation of the written requirement of the patent application. 119 F.3d 1559
(Fed. Cir. 1997). In this case, the Regents of the University of California brought action against Eli Lilly
& Company alleging infringement on several patents for the manufacture of human insulin.79 The court
cited several different specifications for adequately fulfilling the written description requirement in a
patent application.80 First, the court stated that a patent application must describe an invention in
sufficient detail to conclude that “the inventor invented the claimed invention.”81 This “sufficient detail”
is satisfied through a plethora of descriptive means such as words, structures, diagrams, formulas,
chemical names, or physical properties.82 When it comes to deoxyribonucleic acid (“DNA”) that codes for
a specific protein, the court stated that in order to claim DNA in a patent application, a very precise
definition is required.83 This definition should be precise because the disclosure of the amino acid
sequence of a protein does not necessarily make the DNA molecules that are encoding the protein
apparent. The DNA molecules that encode the protein are not apparent because the genetic code is
redundant and could generate a large number of DNA sequences that code for the protein.84 Additionally,
the court noted that a definition by function does not define the genus itself, as it describes what it does as
opposed to what it is.85 Ultimately, this case indicates that in order to satisfy the written requirement, a
definition by function is usually not sufficient and neither is a disclosure of an amino acid sequence of a
protein.86

78

Id.
Regents of Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1562 (Fed. Cir. 1997).
80
Id.
81
Id. at 1566.
82
Id.
83
Id. at 1567.
84
Id.
85
Id. at 1568.
86
Id.
79
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The next case discussed, Centocor Ortho Biotech, Inc. v. Abbott Labs., 636 F.3d 1341 (Fed. Cir.
2011), provides insight into a portion of the written requirement of a patent application that is often
referred to as “the antibody exception.” In this case, Centocor brought suit against Abbott Labs alleging
infringement on a medication that utilized antibodies to treat arthritis.87 The court referenced the
description guidelines from the U.S. Patent and Trademark Office (“USPTO”) discussing the “antibody
exception.”88 These guidelines indicated that a claim referencing an isolated antibody capable of binding
to a specific protein is described adequately if the specification fully characterizes the protein and that this
claim does not need to include working or detailed example(s) of actual antibodies that bind to the
protein.89 The court then elaborated that this example (which is often referred to as the antibody
exception), assumes that the patent applicant is first disclosing a new protein and then claiming both the
antibody that binds to it and the protein itself.90 Finally, the court indicated because precedent implies the
written description requirement for antibody claims can be satisfied through the disclosure of an antigen
that is well-characterized, so can antigens that are newly characterized, so long as the antibody creation
that is claimed is routine.91
The Centocor case set forth the precedent for the “antibody exception,” which led to many broad
antibody claims regarding the written requirement. In the area of patent law, a traditional interpretation of
the written description requirement would have required a characterization of the antibody that was more
specific than the broad claims permitted because of Centocor. However, the antibody exception set forth
the precedent that if the applicant can characterize the structure of an antigen, then the applicant can claim
an antibody against the antigen.92 The “antibody exception” doctrine, as first defined in Centocor,
described the relationship like a “lock and key” mechanism, to mean that if an antigen can be

87

Centocor Ortho Biotech, Inc. v. Abbott Labs., 636 F.3d 1341, 1343 (Fed. Cir. 2011).
Id. at 1351.
89
Id.
90
Id.
91
Id. at 1352.
92
Monoclonal Antibody Patents: Evolving Law & Strategies, FENWICK INSIGHTS, (Oct. 1, 2012)
https://perma.cc/5ZPJ-L5TV.
88
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characterized to a certain level of detail, then the creation of an antibody that would bind to that antigen
would be straightforward.93
AbbVie Deutschland GmbH & Co. v. Janssen Biotech, Inc., provides insight into patenting
antibodies generally, as well as patenting a genus or group of antibodies. 759 F.3d 1285 (Fed. Cir. 2014).
In this case, AbbVie sued Janssen Biotech, alleging infringement on several patents that Janssen
possessed on a human IL-12 neutralizing antibody drug that was marketed under the name Stelara.94
AbbVie’s patent claimed a class of antibodies defined by their high affinity and neutralizing activity to a
known antigen, human IL-12.95 The court had to determine if the patents at issue sufficiently described
the representative species to support the entire genus of the antibodies.96 The court concluded that
AbbVie’s patents described only one type of antibody that was structurally similar, not an entire genus.97
However, the court noted that claims that functionally define a genus can be vulnerable to a challenge for
lack of written support, especially in fields where the technology claimed is highly unpredictable.98 This
vulnerability exists because it can be difficult to establish that a correlation exists between the function
and structure for an entire genus and precisely what the functionally claimed genus would cover.99
Importantly, the AbbVie case served to narrow the “antibody exception” for the written disclosure
requirement, as it indicated that in order for this requirement to be satisfied and an applicant have the
ability to claim a genus, that applicant would need to disclose all of the potential antibody structures that
the patent intends to cover.100 This narrowing of the antibody exception led to a shift where many
companies would include the amino-acid sequences in their disclosure, labeled as residues of the target
antigen of the antibody, which was the case for the patent application in Amgen.101

93

Id.
AbbVie Deutschland GmbH & Co. v. Janssen Biotech, Inc., 759 F.3d 1285, 1289,1292 (Fed. Cir. 2014).
95
Id. at 1299.
96
Id.
97
Id. at 1300.
98
Id. at 1301.
99
Id.
100
Id.
101
Amgen Inc. v. Sanofi, 987 F.3d 1080, 1083-84 (Fed. Cir. 2021).
94

12
https://scholarship.law.uc.edu/ipclj/vol6/iss1/7

12

Taylor: The Patentability of Antibodies for Use in Medications After Amge

Amgen v. Sanofi
The Amgen case had a long history of ongoing litigation beginning October of 2014 when
Plaintiffs, Amgen, Inc., Amgen USA Inc., and Amgen Manufacturing, Ltd., filed suit in the U.S. District
Court for the District of Delaware, alleging that Defendants, Sanofi, Sanofi-Aventis U.S. LLC, Regeneron
Pharmaceuticals, Inc., and Aventisub LLC infringed several of the plaintiffs’ U.S. patents.102 These
patents were then tried based on their validity in front of a jury in March of 2016, where the district court
granted judgement as a matter of law based upon nonobviousness and a lack of willful infringement.103
Notably, the jury found that the patents were not invalid due to a lack of written description.104 Sanofi
appealed, and the U.S. Court of Appeals for the Federal Circuit found that the district court erred in
finding that the patents were valid.105 As a result, the U.S. Court of Appeals for the Federal Circuit
remanded back to the lower court for a new trial on the issues surrounding Sanofi’s defense that the
patents in question lack both the enablement and written description requirements.106 On remand, the
district court found that Sanofi’s claims were invalid for a lack of both written description and
enablement, which the Federal Circuit Court ultimately affirmed.107
Amgen owns the two patents at issue in this case: U.S. Patent No. 8,829,165108 (commonly
referred to as the “'165 patent”) and U.S. Patent No. 8,859,741109 (commonly referred to as the “'741
patent”).110 These patents describe the antibodies utilized in Repatha, where antibodies lower LDL levels
by binding to PCSK9 and preventing it from binding to LDL receptors.111 They share a common written
description, specifying that the antibody to be patented is an isolated monoclonal antibody, and that when

102

Amgen Inc. v. Sanofi, Civil Action No. 14-1317-RGA, 2019 U.S. Dist. LEXIS 146305, at *2 (D. Del. Aug. 28,
2019).
103
Amgen, 987 F.3d at 1083-84.
104
Id. at 1084.
105
Id.
106
Id.
107
Id. at 1084, 1088.
108
U.S. Patent No. 8,829,165 (issued Sept. 9, 2014).
109
U.S. Patent No. 8,859,741(issued Oct. 14, 2014).
110
Amgen, 987 F.3d at 1083.
111
Id.

13
Published by University of Cincinnati College of Law Scholarship and Publications, 2021

13

The University of Cincinnati Intellectual Property and Computer Law Journal, Vol. 6, Iss. 1 [2021], Art. 7

bound to PCSK9, the antibody binds to at least one (or more) of a list of 15 amino acids (described as
residues).112 The written description also includes amino acid sequences for 26 antibodies, one of which is
the antibody utilized in Repatha.113 Additionally, the written description discloses the three-dimensional
structures for two antibodies and the location where those two antibodies bind to PCSK9.114
The primary area of the court’s analysis in Amgen is in determining if the claim at issue satisfies
the requirements in 35 U.S.C. § 112.115 The court initially focused on the enablement requirement, stating
that to prove the invalidity of a claim due to a lack of enablement, one must present clear and convincing
evidence that a person of ordinary skill in the art would have to undergo “undue experimentation” to
practice this claimed invention.116
The court then turned to the eight Wands factors, which establish a factual method of analyzing
whether undue experimentation is necessary.117 The Wands factors are: (1) the amount of necessary
experimentation, (2) the amount of either guidance or discretion that is presented, (3) the existence (or
lack thereof) of working examples, (4) the nature of the invention itself, (5) the state of similar preexisting
art, (6) the skill of those who are in the art, (7) the predictability (or lack thereof) of the art, and (8) the
breadth of the claims at stake.118 Amgen argued that under these factors, no undue experimentation is
necessary to obtain the antibodies that are within the scope of the claims, whereas Sanofi argued that
undue experimentation is necessary.119
The court stated that applying the Wands analysis requires the concrete identification of some or
all of the embodiments asserted to not be enabled.120 This must occur in order to concretely demonstrate
breadth as opposed to an abstract possibility regarding the level of experimentation necessary to make or
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use the product or processes in question.121 The court also held that, “while functional claim limitations
are not necessarily precluded in claims that meet the enablement requirement, such limitations pose high
hurdles in fulfilling the enablement requirement for claims with broad functional language.”122 The court
essentially indicated that it is incredibly difficult to fulfill the enablement requirement in claims where
broad function language is used.123 This broad functional language is like the language used to describe
the antibodies to be patented in this case.124 The court highlighted that the claims in this case are defined
by functional limitations as opposed to structure, indicating that the functional breadth of the antibodies in
question was a major source of concern.125 Ultimately, the court agreed with the district court that the
level of specification present in these claims did not enable preparation without undue experimentation.126
The court highlighted that in limiting the claims to how and what the antibodies bind to, this factor alone
would be sufficient to require one of ordinary skill to experience undue experimentation.127
Notably, the court did mention one mitigating factor although it did not have a drastic impact on
the decision itself.128 The court recognized that the field of science where several patents were at issue is
unpredictable in terms of satisfying the full scope of functional limitations necessary under 35 U.S.C. §
112.129
Ultimately, the court held that undue experimentation would be necessary to practice the full
scope of the claims at issue in this case.130 The court stated that the primary reasoning for this decision
was that the evidence demonstrated that the scope of the claims at issue encompassed millions of potential
candidates that are claimed with respect to a multitude of specific functions.131 As a result, generating and
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screening each antibody candidate would be necessary to determine if that candidate adheres to the
necessary limitations set forth by the claim stating the dual-function of each antibody.132 Additionally, the
court stated that the Wands factors do not indicate that the screening of antibodies never requires undue
experimentation.133
Essentially the ruling in Amgen indicated that broad functional language would no longer be
acceptable to satisfy the enablement requirement as laid out in 35 U.S.C. § 112, since language such as
this would require “undue experimentation” by a person having ordinary skill in the art to practice or use
the claimed invention.134 The court’s reasoning came from its analysis of the Wands factors,
which indicated that Amgen’s broad functional patent claims, given the breadth of those claims, set the
bar too high under the enablement requirement.135 The court indicated that had the claims been based
upon structure as opposed to function, the outcome could have been different.136 The court noted that the
analysis using the Wands factors in and of itself did not indicate that antibodies never require undue
experimentation.137 In Amgen, the Federal Circuit held that in order for one to obtain broad patent
coverage for a class of antibodies that perform a specific function and bind to a specific antigen, one must
meet one of two criteria.138 A company must disclose an adequate number of antibodies that are
representative of this function across the genus one is attempting to claim, or establish that a clear
relationship exists between the antibody’s function and the genus of the antibody that is present in the
company’s specification.139 Ultimately, the ruling in Amgen provided a stark contrast to claims where
antibodies used in medications had been patented in the past, given that broad functional claims had
previously been considered acceptable in satisfying the enablement requirement.140 This raised the bar for
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protecting antibody inventions as the amount of data required when disclosing and claiming antibodies
has significantly increased with the court’s decision in Amgen.141
How Has/Will the Amgen Decision Impact the Process and Patentability of Antibodies?
As the Amgen v. Sanofi decision indicated that broad functional claims are no longer acceptable
or sufficient to satisfy the enablement requirement of a patent application for antibodies, this begs the
question: how has and how will this decision impact both the process and patentability of antibodies for
use in medications? In the United States, six of the top ten drugs, when ranked by revenue, are drugs
utilizing antibodies in some way.142 Due to the Amgen decision, it is estimated that there will likely
continue to be patentability issues surrounding antibody patents and patent applications that were drafted
several years prior to the court’s decision in Amgen.143 As the decision in Amgen v. Sanofi shifted how
antibodies are patented and what antibody claims are sufficient to satisfy both the written and enablement
requirements, this could endanger the patent protection of not only those medications, but others that are
currently patented as well as those that have yet to be patented.144 This shift in what is considered
sufficient to satisfy the necessary requirements to patent an antibody drug has already and will likely
continue to impact the process of patenting antibodies, as well as encourage companies to get creative in
searching for alternative methods for protecting their antibody medications.
Any major decision in a particular area of law is bound to impact future analysis or thought
within that area. Therefore, the same can be said regarding the process of patenting antibodies for use in
medications. The decision by the Federal Circuit in Amgen substantially “raised the bar” for obtaining
broad patent protections of monoclonal antibodies used in therapeutics to satisfy the enablement
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requirement of a patent application.145 Additionally, the standard regarding the patent’s specification as a
part of the written description requirement was also increased because of Amgen.146 This higher bar for
both the written description and enablement requirement from the Amgen decision creates a list of
additional demands that those seeking patent protection of antibodies must meet, which will likely create
some challenges in regards to the process and patentability of monoclonal antibodies used in
therapeutics.147 For example, because of the Amgen decision, it is likely that patent examiners will
become much more conservative when it comes to their grants.148 As a result of this, patent examiners are
likely to reject these broader claims for the patenting of antibodies.149 Therefore, individuals who are
seeking to patent an antibody would have to fight for their application through the Patent Trial and
Appeal Board, and eventually, the Federal Circuit.150 This higher bar for antibody medication patent
protection would ultimately make it more difficult for those seeking patent protection to obtain an
antibody patent, as it would require additional time, money, and research in order to satisfy the new
antibody patenting requirements following the Amgen decision.151
Although Amgen created its own set of difficulties and issues moving forward, there are clear
positive impacts that may come about. One positive impact is the increase in competition because the
Amgen decision suggests that there are ways that companies will be able to either invent around or
challenge a claim that prevents them from inventing around a patent for a given antibody patent that
achieved the same goal first.152 This will then lead to an increase in competition, which is not inherently a
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negative outcome from this decision as currently there is not a significant amount of competition when it
comes to biologics, such as medications that utilize antibodies.153
Not only could the Amgen decision lead to an increase in competition, it could also lead to an
increase in innovation.154 Had the Amgen decision allowed broad functional claims to continue to remain
valid, it could have prevented other companies from making improvements within that class of antibodies
in the future.155 Often when a particular class of antibodies is being developed for therapeutic drug use,
each subsequent antibody created within that class has one, if not more, additional or enhanced
feature(s).156 If the broad functional claims over an antibody class, like those in Amgen, were upheld, this
could prevent these incremental improvements within a particular antibody class from being developed
due to infringement as they would still be present within the same antibody class.157 Therefore, the Amgen
decision could lead to an increase in innovation as subsequent incremental improvements on a class of
antibodies would not constitute infringement on a patent for the entire class.158 This would be beneficial
for patients as it would allow for the creation of more effective medications that were able to treat and
manage illness and symptoms more effectively. Therefore, the Amgen decision will likely lead to an
increase in innovation as it will create an incentive for companies to be more innovative in their
development of antibody medications, but this incentive comes from the inability to secure patent claims
that are broad and purely functional, failing to adequately describe the structures disclosed.159
Additionally, although the Amgen decision will pose some difficulties and challenges for those
companies who are trying to obtain an antibody patent for a particular medication, this prevents those
seeking antibody patents from claiming more than they have actually discovered.160 Getting rid of the
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ability to broadly claim more than what one has truly discovered could lead to the lowering of the price of
medications utilizing antibodies, which could prove to greatly benefit patients.161 In obtaining a large
number of extremely broad patents, companies are able to pile on protections of the new drug they are
creating.162 Obtaining a large number of broad patents will keep competitors who would be able to
produce the same drug for a lower cost out of the market for a significant period of time.163 This leads to a
substantial amount of income for the companies that hold these broad antibody patents.164 In making it far
more difficult, if not impossible, to obtain these patents, competition will be increased within the market
for medications that utilize antibodies, thus lowering prices for patients.165
Ultimately, the Amgen decision has altered the way antibodies for use in medication are patented,
through preventing broad functional claims from continuing to satisfy the enablement requirement.
Although this will inevitably make it more difficult for companies to obtain patents for antibody drugs, it
also will likely have several positive effects that will ultimately help patients, such as, those relating to
competition, innovation, and lowering prices for patients. As a result of these difficulties created in the
wake of the Amgen decision, it is possible that some companies will instead turn to alternative methods in
order to avoid these difficulties caused by the Amgen decision.
Alternative Methods of Antibody Protection
Given that it is unclear how antibodies claimed at the genus level for use in medications can be
patented following the Amgen v. Sanofi decision, companies may turn to alternative methods outside of
the patent process of claiming an entire genus of antibodies to seek protection over their antibody drugs
that perhaps would otherwise have a low patentability. There are a plethora of various methods that could
be utilized to help protect antibody drugs that are not patentable due to broad functional claims following
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the Amgen decision.166 The top three methods include: trade secret protection, attempting to patent the
antibody based on homology, and accession deposits, among many others.167 Each of these methods has
benefits as well as drawbacks, and the costs and risks associated with these options compared to the
process in which antibodies were patented in the past will need to be weighed carefully by each company
seeking protection over a particular antibody drug.168
There are several alternative methods of antibody drug protection that still involve the patent
process yet avoid the broad functional claims that are no longer permitted under the Amgen decision.
These methods, if utilized by companies seeking protection of their antibody drugs, could still allow for
patent protection, although the claims within the patent application would not be broad or merely
functional. One example of an alternative method of antibody drug protection utilizing the patent system
would be to patent a specific antibody sequence and antibody sequences that share a certain level or
similarity or homology with those original antibody sequences.169 This process of patenting through
homology could provide a method of protecting the sequence that creates the antibody itself.170
Another option would be for companies to obtain a patent that protects everything except the
antibody itself.171 This patent could include methods of manufacturing the medication, the pharmaceutical
composition of the antibody drug, and other aspects of the medication that do not include the antibody
itself.172 However, this alternative is not without flaw, as it too could raise several questions regarding
functional claims which could potentially cause issues rooted in the court’s decision in Amgen.173
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The patent system provides another option for those seeking robust patent protection of a
monoclonal antibody medication, the layering process.174 The concept and process of layering involves
both the filing of multiple patents and multiple claim scopes temporarily.175 Protecting antibody drugs and
obtaining patent protections could be achieved in several different ways.176 For example, the subject
matter of each patent “layered” should be claimed using a variety of different formulas which create
differences in scope.177 This way, even if some of the claims are invalidated as a result of a post-grant
challenge, the other claims that were presented within the patent application would remain valid.178
Furthermore, the patent portfolio could be staggered chronologically so that a range of different patent
claims are included within the portfolio, thus extending the term in which the patent application was
initially filed.179
Additionally, adding back up claims is another method that can be utilized within the patent
process to help increase the patentability of antibodies following the court’s decision in Amgen where
broad functional claims were deemed to be insufficient to secure patent protection for antibody
medication would be adding backup claims.180 When a patent applicant adds backup claims, they are
essentially also including a set of narrower claims within the patent application.181 These narrower claims
include various aspects of the antibody such as portions of the antibody’s sequence or combining
functional and structural elements within the same claim, which will increase the patent’s chance of
withstanding a challenge, and therefore the patentability of the antibody.182 In adding these backup claims
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to the patent application for an antibody drug, companies would be increasing the patentability of that
drug as it would magnify the chances that the entire patent is invalidated in a post-grant challenge.183
Another example of an alternative method would be to utilize trade secret protection.184 The U.S.
Food and Drug Administration provides twelve years of exclusivity through the trade secret process, and
companies may simply hold on to their inventions as trade secrets for this time, skipping the patent
process entirely.185 Although this solution would avoid the risks associated with disclosing information
through the patent process in regards to how their antibody medications achieve the desired result, it also
presents its own challenges.186 However, utilizing trade secret protection as an alternative solution to
claiming patent protection could raise questions regarding the Biologics Price Competition and
Innovation Act, as well as questions regarding biosimilar competition.187 These questions present a
problem as without a patent disclosing exactly what the antibody is designed to bind to, it would then
need to be determined if that information regarding the antibody’s function, which would potentially be
protected as a trade secret, would need to be disclosed through the Biologics License Application
approval process.188 Additionally, it would require a determination of whether or not biosimilars would or
should have access to that potentially protected information or not.189 Protecting antibody medications
through trade secret protection presents a problem as it could prevent the dissemination of information
and advancements in regard to future antibody medication developments. Preventing information about
future antibody medications from being shared would go against the further production of science and the
overall goal of improving medications for future use. The issues caused by protecting antibodies with
trade secret protection demonstrates that although the patent process regarding antibody medications will
prove to cause difficulties for companies looking to patent medications in the future, alternative solutions
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may not prove to be the best solution for combating these difficulties, as they could create a variety of
additional problems.
One final alternative method outside of the patent process of claiming an entire genus of
antibodies to seek protection over an antibody drug that perhaps would otherwise have a low patentability
is an accession deposit. An accession deposit occurs when a company takes a sample of the antibody for
which they are seeking protection and deposits this sample at an accession deposit organization.190 Then,
the company would use that deposit at the accession deposit organization as a reference for their patent
claims in the process of patenting the antibody.191 This process is rarely done and, likely would not occur;
however, it still is a potential option that a company could use when seeking an alternate method of
antibody medication protection following the Amgen decision.192
Ultimately, these alternative methods to the new standards for monoclonal antibody medication
patent protection in the wake of the Amgen decision all have benefits as well as downsides, and each
method of protection is associated with varying levels of risk. Although some companies may choose to
seek alternative methods or layer in additional protections to their patent applications so that their
antibody drugs will have an increased likelihood of patentability due to the changes and increased
difficulties caused by the Amgen decision, it is highly unlikely that these changes in patent protections
will cause pharmaceutical companies to stop making antibody drugs.193 As mentioned previously,
antibody drugs are massively profitable, with some bringing in tens of billions of U.S. dollars a year.194
Although these alternative methods may provide a way for companies to obtain additional patent
protection or avoid some of the difficulties of the changes caused by Amgen, companies will likely still
seek to create and obtain protection for these antibody medications, regardless of their patentability.
How Will the Amgen Decision Impact Future Attempts to Patent Antibodies?
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Now that a thorough discussion has occurred in regard to the impact that the Amgen v. Sanofi
decision has had and will continue to have on the process and patentability of antibodies, one question
still remains: how will this decision impact future attempts to patent antibodies for use in medications? As
mentioned previously, the debate over whether antibodies can be claimed and protected by a patent
broadly at the genus level has been ongoing.195 Those in support of claiming antibodies at a genus level
have based their argument around the idea that since scientists have a tendency to define antibodies based
on what they bind to.196 However, the Federal Circuit, in the Amgen decision has strongly indicated, so
much so that it can no longer be questioned, that there is no longer an exception present for antibodies,
indicating that antibodies can no longer be claimed or under patent protection at the genus level in the
way that they were previously.197 Ultimately, this shift will make it more difficult for patent applicants to
obtain patent protection for their monoclonal antibody drugs. However, this increase in difficulty will also
help to avoid some of the previously mentioned problems that can occur as a result of permitting genus
level patent claims.
As a result of the Federal Circuit’s decision in the Amgen case, future attempts to patent
antibodies will be affected by this shift.198 Following the Amgen decision, companies will no longer be
able to define and claim antibodies purely based on function alone.199 Those looking to patent antibodies
moving forward will have to tie their patent claims to the antibody’s structure to some degree.200
Including the antibody’s structure within a patent claim could be satisfied in a variety of ways, such as
identifying particular amino acids that might be substituted within the protein sequence disclosed in the
patent application, an exact description of an amino acid sequence, or a percent identity to an amino acid
sequence.201 Additionally, the antibody’s structure could be listed in the claim through the inclusion of the
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variable domains of the heavy and light chains.202 These structural claims have always been useful in
protecting antibodies that are innovative.203 It is highly likely that structural claims will continue to be
useful in the future for those seeking to patent antibody medications following the Amgen decision, as
using structural claims eliminates patentability for those who do not adequately disclose the antibody’s
structure within the patent application and instead base their claims on the antibody’s function.204
Moving forward with future attempts to patent antibodies, it has become significantly more
important for patent applications to analyze each antibody on a case-by-case basis.205 Antibodies should
be analyzed in this way so that patent applicants can determine which features should be claimed, and
how the claims can be most effectively made based upon the amount of investment, data, and research
pertaining to the antibody available.206 In carefully selecting and analyzing the features to be claimed,
companies seeking patent protection in the future can increase the likelihood that at least some, if not all,
of the claims made within their patent applications will remain patentable even when the patent faces
invalidation.207
Additionally, the court’s decision in Amgen will make the process of patenting antibodies for use
in medications in the future far more expensive than they were previously. The process of developing
antibody drugs is incredibly complex and very expensive.208 On average, medications that utilize
antibodies cost around 2.6 billion dollars to bring to the market.209 In narrowing how antibodies can be
patented with the Amgen decision, this process will likely become even more expensive for companies
looking to develop new antibody biologics as more research and information is required to satisfy the

202

Id.
Id.
204
Id.
205
Dani Kass, Biologics Face Tougher Patent Scrutiny After Amgen Ruling (Feb. 18, 2021) https://perma.cc/C9JY6PPQ (last visited Oct. 15, 2021).
206
Id.
207
Id.
208
Dani Kass, Pharma Giants Tee Up Biologics Innovation Fight At Fed. Circ. (Aug. 21, 2020)
https://perma.cc/2QNH-7J6D (last visited Oct. 15, 2021).
209
Id.
203

26
https://scholarship.law.uc.edu/ipclj/vol6/iss1/7

26

Taylor: The Patentability of Antibodies for Use in Medications After Amge

written and enablement requirements post Amgen.210 Furthermore, in the process of developing these
medications, it is possible that a company may have over 50 promising candidates at a time, which makes
it more difficult for that company to know when to file a patent application.211 This is because the Amgen
decision requires additional research and information to be presented to satisfy the written and
enablement requirements, and if a company waits until they have that much information and have
narrowed the promising antibody candidates to only a few, it is possible that someone else may have
already filed an application overlapping with those antibody candidates.212 If someone had already filed
an application overlapping with those candidates, this would lead to a waste of both time and money,
making the process of developing antibody based medications more expensive. This increase in cost is
simply another hurdle that those attempting to patent antibody drugs in the future will have to overcome.
The Amgen decision drastically changed the antibody patenting process and created a plethora of
questions that have yet to be answered. These questions have already made it much more difficult for
attorneys working within patent law to know or understand exactly what to advise their clients who are
hoping to patent antibodies to be used in various medications.213 The process of patenting antibodies is
more difficult for attorneys following the Amgen decision because, although the Federal Circuit has said
that it is theoretically possible to patent an antibody genus, the Federal Circuit has yet to provide an
example of where the necessary requirements would be met in order for an antibody genus to be
patented.214 Instead, the Federal Circuit has provided several instances where the written description and
enablement requirements were not satisfied, such as stating that the 26 examples present in the Amgen
decision and the 300 examples present in the AbbVie decision were not sufficient to satisfy these
requirements.215 Therefore, as the Federal Circuit has not made it clear what is necessary to satisfy the
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written description and enablement requirements for those seeking patent protection of antibodies to be
used in medication, this lack of clarification from the Federal Circuit creates a wide variety of problems
for those companies that spend a substantial amount of money creating these medications.216 These
problems and unanswered questions pose additional hurdles for patent applicants seeking protection over
antibody medications. However many of these questions will likely be answered and some of these
concepts will continue to receive attention from the court in the future, as issues with antibody drug patent
claims continue to arise.217
Conclusion
In conclusion, the Amgen decision in 2021 drastically changed the U.S. patent system regarding
the patentability of antibodies. In Amgen, the Federal Circuit held that broad functional claims were not
sufficient to satisfy the enablement requirement.218 Ultimately, this decision provided a stark contrast to
claims where antibodies used in medications had been patented in the past, given that broad functional
claims had previously been considered acceptable in satisfying the enablement requirement.219 In
providing this contrast, the Amgen decision raised the bar for protecting antibody inventions as the
amount of data required when disclosing and claiming antibodies has significantly increased with the
court’s decision in Amgen.220 The Amgen decision has and will continue to vastly impact the process and
patentability of antibodies. inevitably making it more difficult for companies to obtain patents for
antibody drugs. As a result of these difficulties created in the wake of the Amgen decision, some
companies will instead turn to alternative methods to avoid these difficulties. However, the Amgen
decision also will likely have several positive effects that will ultimately help patients, such as, those
relating to competition, innovation, and lowering prices for patients. Moving forward, those looking to
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patent antibodies in the future will instead have to tie their patent claims to the antibody’s structure to
some degree.221 Additionally, companies seeking patent protection will need to carefully select and
analyze the antibody features to be claimed to increase the likelihood that at least some, if not all, of the
claims made within their patent applications will remain patentable even when the patent faces
invalidation.222 The Amgen decision will also likely increase the cost to companies seeking to develop
antibody drugs due to the additional research and information that are now required as a part of the patent
application due to Amgen.223 However, despite these additional difficulties caused by Amgen and the shift
that it has caused in the process and necessary requirements for patenting antibodies used in medications,
pharmaceutical companies will likely still develop and create new antibody medications for years to
come. Ultimately, drugs utilizing antibodies are some of the highest grossing drugs in the United States
and why would a biologic company stop producing and creating new drugs that gross billions of dollars
each year?224
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